Raloxifene

Raloxifene hydrochloride is developed by Eli Lilly & Company and it has been approved by FDA since 1997.Its approval was expanded in 2007 to reduce the risk of invasive breast cancer in women at higher risk or those with osteoporosis Was initially used to manage osteoporosis in postmenopausal women by enhancing bone density. Today marketed under the Evista brand, Raloxifene remains a leading SERM with its dual action of protecting bone and minimizing cancer risks​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.